Gene
CDK4
CDK4 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (27), Actionable biomarkers (8), Trial mentions (947), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention CDK4. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers. Not plotted: 2 with a planned future start and 1 with no date at all.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 14 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 98 of 8,738 | 1.12% | not measured | |
| 2025 | 108 of 8,875 | 1.22% | not measured | |
| 2024 | 131 of 8,597 | 1.52% | not measured | |
| 2023 | 107 of 8,275 | 1.29% | 37 of 11,460 | 0.32% |
| 2022 | 101 of 8,285 | 1.22% | 66 of 13,598 | 0.49% |
| 2021 | 77 of 8,692 | 0.89% | 61 of 15,045 | 0.41% |
| 2020 | 71 of 7,640 | 0.93% | 53 of 14,459 | 0.37% |
| 2019 | 77 of 7,300 | 1.05% | 43 of 12,159 | 0.35% |
| 2018 | 41 of 6,927 | 0.59% | 44 of 11,854 | 0.37% |
| 2017 | 48 of 6,558 | 0.73% | 38 of 11,595 | 0.33% |
Showing 10 of 37 years.
Assay-provider ledger (27)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Foundation Medicine | Diagnostic provider | Clinical validationAnalytical validation | 4 | December 01, 2021 |
| The King Kong Corp. Ltd. | Reagent supplier | No clinical or analytical validation recorded for this pair | 1 | May 29, 2021 |
| Guardant Health | Diagnostic provider | Clinical validation | 1 | September 01, 2020 |
| National Cancer Center, Tokyo, Japan (NCC Oncopanel) | Not a company | Clinical validation | 1 | September 01, 2020 |
| THERMO FISHER SCIENTIFIC (Click-iT EdU kit, TaqMan Low-Density Array reagents, ExpressionSuite/DataAssist software) | Reagent supplier | Clinical validationAnalytical validation | 2 | September 01, 2020 |
Showing 5 of 27 assay-provider companies.
Actionable biomarkers (8)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| CDK4 amplification + RB1 expression | Cdk4 Inhibitors | response-associated | liposarcoma | Cancer Genome Interpreter |
| CDK4 oncogenic mutation | Lee011 | response-associated | liposarcoma | Cancer Genome Interpreter |
| CDK4 amplification | Lee011 | response-associated | liposarcoma | Cancer Genome Interpreter |
| CDK4 amplification | Palbociclib | resistant | lung carcinoma | Cancer Genome Interpreter |
| CDK4 oncogenic mutation | Lee011 | response-associated | lymphoma | Cancer Genome Interpreter |
Showing 5 of 8 actionable-biomarker assertions.
Trial mentions (947)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT04660435 | Trial biospecimen (AACT) |
| NCT06450301 | Trial biospecimen (AACT) |
| NCT07407439 | Trial biospecimen (AACT) |
| NCT05304962 | Trial eligibility (AACT) |
| NCT06025747 | Trial eligibility (AACT) |
Showing 5 of 947 trial mentions.
Target-disease associations (673)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 46 XX gonadal dysgenesis | endocrine system disease | Mouse knockout (IMPC) |
| 46,XX gonadal dysgenesis | endocrine system disease | Mouse knockout (IMPC) |
| 46,XX ovotesticular disorder of sex development | endocrine system disease | Mouse knockout (IMPC) |
| 46,XX sex reversal 1 | endocrine system disease | Mouse knockout (IMPC) |
| 46,XX testicular disorder of sex development | endocrine system disease | Mouse knockout (IMPC) |
Showing 5 of 673 associations.
Vendor sourcing (3,230)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 1 Million 4 Anna Foundation | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Age ≥ 12 years and ≤ 50 years at time of enrollment. * Karnofsky performance status ≥ 50% for patients ≥16 years of age and Lansky ≥ 50% for patients \<... | View trial NCT04129151 |
| 1 Million 4 Anna Foundation | Trial collaborator | Mentioned in trial textTrial free-text mention | CDK4 | View trial NCT04129151 |
| 100 Voices of Hope | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Age ≥ 18 years at the time of informed consent 2. Ability to provide written informed consent and HIPAA authorization 3. Diagnosis of DCIS or stage I, ... | View trial NCT07825454 |
| 100 Voices of Hope | Trial collaborator | Mentioned in trial textTrial free-text mention | CDK4 | View trial NCT07825454 |
| A.O.U. Federico II, Napoli | Trial collaborator | Named in trial exclusion criteriaTrial eligibility criteria | : * Less than 3 months of follow up from the CDK4/6i start to the date of data cut-off; * Have received CDK4/6i as monotherapy; * Have received CDK4/6i as a... | View trial NCT06805812 |
Showing 5 of 3,230 sourcing records.
Trial-cited literature (588)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial. | The Lancet. Oncology | 2026 | 5 |
| Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. | The Lancet. Oncology | 2025 | 3 |
| The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia. | Blood neoplasia | 2025 | 3 |
| Updated efficacy and predictive biomarkers of QL1706, a bifunctional PD-1/CTLA-4 dual blocker in advanced solid tumors-A phase 1/1b study. | Cell reports. Medicine | 2025 | 2 |
| Dalpiciclib combined with pyrotinib and endocrine therapy in women with ER-positive, HER2-positive advanced breast cancer: A prospective, multicenter, single-arm, phase 2 trial. | PLoS medicine | 2025 | 1 |
Showing 5 of 588 papers.
Protein variant mentions (29)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A77A | 1 | 2014 | PMID 25780468 |
| p.A79A | 1 | 2014 | PMID 25780468 |
| p.D129N | 1 | 2016 | PMID 26467025 |
| p.D221N | 1 | 2016 | PMID 26467025 |
| p.E115D | 1 | 2016 | PMID 26467025 |
Showing 5 of 29 variants.
Literature-extracted relations (190)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| FULVESTRANT | Chemical | negative_correlate |
Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial. | 2023 |
| TRASTUZUMAB | Chemical | negative_correlate |
A phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN). | 2023 |
| Letrozole | Chemical | negative_correlate |
A multicentre single arm phase 2 trial of neoadjuvant pyrotinib and letrozole plus dalpiciclib for triple-positive breast cancer. | 2022 |
| Letrozole | Chemical | negative_correlate |
Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial. | 2021 |
| EVEROLIMUS | Chemical | associate |
Ribociclib and everolimus in well-differentiated foregut neuroendocrine tumors. | 2021 |
Showing 5 of 190 relation assertions.
Organizations publishing (528)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | Hospital | 44 | 2011 to 2024 |
| Dana-Farber Cancer Institute | Other | 41 | 2006 to 2025 |
| Harvard Medical School | Academic | 30 | 2009 to 2023 |
| The University of Texas System | Academic | 25 | 2010 to 2025 |
| Government of the United States of America | Government | 19 | 1996 to 2026 |
Showing 5 of 528 organizations.
Where CDK4 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
577 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.